QRxPharma wins US patent for opioid compounds
QRxPharma (ASX:QRX) has received a US patent covering the development of hybrid opioid compounds.
The patent encompasses a hybrid morphine-oxycodone molecule, where the two opioids are chemically linked. The patent expires in 2031.
QRxPharma is seeking US FDA approval for MoxDuo, a formulation consisting of morphine and oxycodone in the same tablet, and expects a decision on the immediate-release version shortly.
The company already holds a US patent covering the use of morphine and oxycodone in the same capsule, granting protection for both the immediate- and controlled-release versions through to 2023.
But the new patent covers chemically linking the two opioids to form a new composition of matter more potent than they would be if administered separately.
QRxPharma CEO Dr John Haloday said the new patent “protects next-generation dual-opioid combination products that are chemically unique”.
The company has licensed MoxDuo IR to Actavis in a deal worth up to US$150 million ($158.9 million).
QRxPharma shares were trading unchanged at $1.19 as of around 1 pm on Thursday.
Indigenous-led initiative to resurrect the South Island Giant Moa
New Zealand's Ngāi Tahu Research Centre has partnered with Colossal Biosciences and Sir Peter...
Abnormal brain protein targeted in Parkinson's study
Researchers have identified a new brain protein involved in the development of Parkinson's...
Epilepsy disease model treated in a laboratory dish
A research team has used an epilepsy-like disease model in a laboratory dish to demonstrate that...
